Publications > Journals > Journal of Clinical and Translational Hepatology > Article Full Text

  • OPEN ACCESS

UGT1A1-related Bilirubin Encephalopathy/Kernicterus in Adults

  • Jie Bai1,2,# ,
  • Lu Li1,#,
  • Hui Liu3,
  • Shuang Liu2,
  • Li Bai2,
  • Wenyan Song4,
  • Yu Chen1,2,
  • Sujun Zheng1,2,*  and
  • Zhongping Duan1,2,*
 Author information
Journal of Clinical and Translational Hepatology 2021;():-

DOI: 10.14218/JCTH.2020.00108

Abstract

Background and Aims

Bilirubin encephalopathy/kernicterus is very rare in adults. This study is aimed to investigate the clinical manifestations and genetic features of two patients with UGT1A1-related kernicterus.

Methods

Sanger sequencing analysis was performed to identify UGT1A1 gene mutations in the patients and their families. Bioinformatics analysis was used to predict the potential functional effects of novel missense mutations. Clinical manifestations and biochemical parameters were collected and analyzed.

Results

Two patients with Crigler-Najjar syndrome type II (CNS2) developed kernicterus in adulthood. Sanger sequencing identified a compound heterozygous mutation in the UGT1A1 gene in patient 1, which was inherited from his mother (G71R) and his father (c.-3279T>G; S191F). Patient 2 carried three heterozygous mutations, namely G71R, R209W and M391K; among which, the M391K mutation has not been reported before. Multiple prediction software showed that the M391K mutation was pathogenic. Symptoms were relieved in the two patients after phenobarbital and artificial liver support treatment. Patient 1 also underwent liver transplantation.

Conclusions

Adults with CNS2 are at risk for kernicterus. Phenobarbital treatment is beneficial for maintaining bilirubin levels and preventing kernicterus.

Keywords

Kernicterus, UGT1A1, Crigler-Najjar syndrome type II, Phenobarbital

Introduction

Bilirubin encephalopathy/kernicterus is an uncommon disabling neurologic disease caused by the toxicity of unconjugated bilirubin (UCB) to the basal ganglia and various brain stem nuclei.1 Neonatal jaundice is quite common, affecting 60–80% of newborns, as a whole.2 However, severe hyperbilirubinemia (>20 mg/dL), which may potentially lead to kernicterus and neurodevelopmental complications, is very rare, accounting for less than 2% of newborns.3 The incidence of kernicterus is about 0.2 to 2.7 cases per 100,000 live births.1 Common risk factors may include preterm delivery, hemolytic disease [glucose-6-phosphate dehydrogenase deficiency and ABO hemolysis], perinatal infection and exclusive breastfeeding.1,4

For adults, elevated UCB caused by hemolytic disease and inherited non-hemolytic unconjugated hyperbilirubinemia (bilirubin glucuronidation defects) is relatively common. Bilirubin glucuronidation is regulated by the uridine diphosphate glucuronosyl transferase 1A1 (UGT1A1) enzyme. It is encoded by the UGT1A1 gene, which is located on chromosome 2 (2q37), and covers a promoter, enhancers, and five exons. According to the severity of UGT1A1 enzyme deficiency, inherited unconjugated hyperbilirubinemia can be classified into Crigler-Najjar syndrome type I (CNS1), Crigler-Najjar syndrome type II (CNS2), and Gilbert syndrome (GS).5,6 CNS1 is the most severe form, determined by a complete lack of bilirubin glucuronidation, and patients exhibit a toxic level of hyperbilirubinemia (≥340 µmol/L) shortly after birth.7

CNS1 patients usually suffer from bilirubin encephalopathy, and are prone to death within the first 2 years of their lives.8,9 At present, orthotopic liver transplantation is the only radical treatment.10,11 CNS2 is characterized with not very high bilirubin (from 103 to <340 µmol/L)12 and the bilirubin glucuronidation is less than 10% of normal level but not completely eliminated.13 Although the phenotype of CNS2 is less severe, patients with CNS2 remain vulnerable to brain injury throughout life, especially in the setting of concurrent diseases, after injury, or during surgery.14 Poddar et al.15 reported a case of kernicterus in a CNS2 child due to a dramatic increase in UCB caused by hemolysis. GS is a mild hyperbilirubinemia (from normal level up to 80–100 µmol/L) that occurs in 5–10% of the population,12 with approximately 70% reduction in bilirubin glucuronidation.16 GS is considered as a benign condition without neurological damage and treatment requirement.

At present, there are few reports of kernicterus in adults. Here, we aimed to report two CNS2 adults with UGT1A1 mutations who developed kernicterus.

Methods

Subjects and sample collection

The patients and all family members received careful clinical examinations and laboratory assessments by experienced physicians in Beijing You’an Hospital, Capital Medical University. Fasting blood samples were collected from all participants; clinical manifestations and biochemical parameters were collected and analyzed.

This study was approved by the Ethics Committee of Beijing You’an Hospital, Capital Medical University, and a written informed consent form was obtained from all participants.

DNA extraction and screening for the mutations in UGT1A1

Genomic DNA was extracted from whole blood using a QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany), according to the manufacturer’s protocol. The promoter, all five exons, exon-intron boundaries, and a region in the distal promoter (the phenobarbital response enhancer module, PBREM) of UGT1A1 were amplified by PCR technology, then purified through agarose gel electrophoresis and sequenced using a 3730XL sequencer (Applied Biosystems Inc., Foster City, CA, USA). Finally, Sanger sequencing data were compared and analyzed by SeqMan software (DNASTAR, Madison, WI, USA).

Bioinformatics analyses

Potential functional effects of novel missense mutations were predicted by PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/index.shtml ), SIFT (http://sift.jcvi.org/ ), PROVEAN (http://provean.jcvi.org/index.php ), MutationTaster (http://mutationtaster.org/ ), FATHMM (http://fathmm.biocompute.org.uk/ ), InterVar (http://wintervar.wglab.org/ ), and MutPred2 (http://mutpred.mutdb.org/ ). The grade of conservation of the mutant nucleotides was determined by PhastCons and PhyloP.

Results

Patient 1

The patient was a 32-year-old man with a 30-year history of jaundice. In May 2020, he lost his appetite after drinking (about 500 mL beer, 20 g ethanol). He took Chinese medicine (unknown pharmaceutical ingredients) for a week, but the symptoms were not alleviated. Then, he developed dizziness, headache, and mild neuropsychological disorder. Liver function results were abnormal, with decreased albumin (23.8 g/L) and increased aspartate aminotransferase (commonly referred to as AST; 148U/L), alanine aminotransferase (commonly referred to as ALT; 54 U/L), total bilirubin (TB, 411.8 µmol/L), indirect bilirubin (266.3 µmol/L) and direct bilirubin (145.5 µmol/L). Blood routine test showed a high proportion of neutrophils (81.5%) and a decrease in hemoglobin (109 g/L). His prothrombin time activity was 42% and the Coombs test was negative. Blood ammonia (16 µg/dL), fasting plasma lipids, autoantibodies profile, anti-neutrophil cytoplasmic antibody, and immunoglobulins (Igs) including IgG, IgA, IgM, and IgE were normal. The viral hepatitis markers were negative. Computed tomography (referred to as CT) and magnetic resonance imaging showed hepatosplenomegaly (Supplementary Fig. 1). Brain CT scans were normal (Supplementary Fig. 1). The patient was diagnosed with acute-on-chronic liver failure (ACLF), CNS2 and kernicterus, and received oral phenobarbital, albumin infusion, and anti-infection therapy.

One week after admission, the patient suddenly manifested hematemesis and showed restlessness, then lost consciousness. TB, indirect bilirubin, and blood ammonia levels increased to 532.3 µmol/L, 379.1 µmol/L, and 123 µg/dL, respectively. Gastroscopy revealed cardiac mucosal laceration syndrome (Mallory-Weiss syndrome). The patient was treated with hemostasis, sedation, intramuscular injection of phenobarbital, and artificial liver support treatment of double plasma molecular adsorption system combined with plasma exchange (DPMAS) and plasma exchange. Later, the patient’s consciousness gradually recovered and he underwent liver transplantation. Histopathology of the removed liver showed massive and submassive hepatocyte necrosis, cholestasis, and steatosis (Fig. 1). The patient is now in a relatively stable state. Table 1 and Fig. 2 show his blood test results.

Liver histopathology of patient 1 revealed massive and submassive necrosis, cholestasis and steatosis.
Fig. 1  Liver histopathology of patient 1 revealed massive and submassive necrosis, cholestasis and steatosis.

(A) Hematoxylin-eosin stain, 40 x. (B) Hematoxylin-eosin stain, 200 x. Massive and submassive necrosis, cholestasis and steatosis are indicated by the red box, and black and red arrows, respectively.

Table 1

Biochemical characteristics of patient 1

CharacteristicsReferenceDays after admission
138a13b15c16c17c182425c26
TB (µmol/L)5–21411.8513.6532.3616.4570.3353.8453.3417.8524561.5378.5
IB (µmol/L)<7266.3370.6379.1450.1427.7274.9374.3352.7428.6490.4330.4
DB (µmol/L)145.5143153.2166.3142.678.97965.195.471.148.1
ALB (g/L)40–5523.827.827.439.435.935.746.243.341.342.243.2
BAMR1.11.21.31.01.00.70.60.60.80.90.6
ALT (U/L)9–50546062641308179751089375
AST (U/L)15–40148152147164366207206184207191150
GGT (U/L)10–6011499
ALP (U/L)45–125474412
TBA (µmol/L)<10175.3122.8
WBC (×109/L)3.5–9.56.685.548.267.477.027.26.874.216.254.087.69
N%40–7581.571.180.183.275.872.872.783.475.971.690.1
HGB (g/L)130–1751091121058082788580656268
PLT (×109/L)125–3501451381288587819089857075
Amon (µg/dL)19–54162512379208254859
BAMR in patient 1 after admission.
Fig. 2  BAMR in patient 1 after admission.

Sanger sequencing of the UGT1A1 gene identified a compound heterozygous mutation in this patient, which was inherited from his mother (c.211G>A, p.G71R) and his father (c.-3279T>G; c.572C>T, p.S191F) (Fig. 3 and Supplementary Fig. 2).

Family pedigree of patient 1.
Fig. 3  Family pedigree of patient 1.

The arrow indicates patient 1.

Interestingly, the patient’s elder sister also showed jaundice since childhood. Her TB was about 400 µmol/L. She was diagnosed with CNS2 but had never developed kernicterus. In addition, the patient’s father had mild unconjugated hyperbilirubinemia (TB of 32.1 µmol/L, indirect bilirubin of 23.2 µmol/L) and was diagnosed with GS. They were both also found to carry the same compound heterozygous mutation as the patient (Fig. 3).

Patient 2

The patient was a 35-year-old man. He had been suffering from jaundice since birth, with TB ranging from 70–80 µmol/L. In adulthood, his TB levels were about 300 µmol/L. At the age of 31, he developed right upper abdominal pain and severe jaundice. His TB level had been found to have increased to above 500 µmol/L. The patient was diagnosed with gallbladder stones, cholecystitis and CNS2. After treatment with antibiotics and oral phenobarbital, the patient’s pain was relieved and TB was reduced to 300 µmol/L. Later, the patient experienced repeated abdominal pain, fever, and severe jaundice. In November 2019, he became lethargic and unresponsive after a fever. Then, he developed limb convulsions and urinary incontinence. The patient was admitted on November 15, 2019.

The results of liver function showed decreased albumin (21.5 g/L) and increased AST (222 U/L), ALT (57 U/L), TB (417.4 µmol/L), and direct bilirubin (195 µmol/L). The proportion of neutrophils (88.1%) and blood ammonia (112 µg/dL) were elevated. The Coombs test was negative. The fasting plasma lipids, autoantibodies profile, and anti-neutrophil cytoplasmic antibody were normal. Cerebrospinal fluid results did not suggest central nervous system infection. Abdominal ultrasonography showed gallstones, cholecystitis, and splenomegaly. Brain CT scans were normal.

Sanger sequencing of the UGT1A1 gene identified three heterozygous mutations, namely G71R (c.211G>A), R209W (c. 625C>T), and M391K (c.1172T>A) (Supplementary Fig. 3). The M391K mutation has not been reported before. Seven software programs were used to predict the pathogenicity of the mutation. As shown in Supplementary Table 1, all software programs showed that the M391K mutation was pathogenic or damaging. The PhastCons score of the mutation was 1, and the corresponding PhyloP value was 2.307, suggesting the high conservation of this amino acid.

The patient was treated with antibiotics, sedation, intramuscular injection of phenobarbital, and artificial liver support treatment with DPMAS and plasma exchange. The patient’s neurological status gradually returned to normal. Table 2 and Fig. 4 show the results of his blood investigations.

Table 2

Biochemical characteristics of patient 2

CharacteristicsReferenceDays after admission
145a7b8b912b13
TB (µmol/L)5–21417.4527.7547.3448.9432.5342.1486.2257.1
IB (µmol/L)<7222.4320360322.8322.9260.4361.8217.5
DB (µmol/L)195207.7187.3126.1109.681.7124.439.6
ALB (g/L)40–5521.531.732.832.13529.633.426.7
BAMR1.31.11.10.90.80.81.00.6
ALT (U/L)9–505758595863718863
AST (U/L)15–40222249233171160171191169
GGT (U/L)10–6078767374112
ALP (U/L)45–125513460327282334
TBA (µmol/L)<10159.1148.9137.4136.6133.8
WBC (×109/L)3.5–9.512.775.566.228.359.466.2410.6
N%40–7588.176.679.979.884.77986.7
HGB (g/L)130–1751161081051021029393
PLT (×109/L)125–350237161176176188156173
Amon (µg/dL)19–544110711681741087589
BAMR in patient 2 after admission.
Fig. 4  BAMR in patient 2 after admission.

Discussion

High concentrations of UCB can cause nervous system damage, known as bilirubin encephalopathy or kernicterus. In general, kernicterus is found in infants and young children, especially those who are premature and/or have hemolysis.1,17 On one hand, the blood-brain barrier of newborns and children is immature. On the other hand, the albumin/bilirubin-binding capacity and tissue-binding capacity vary significantly among newborns, and these values are particularly low for premature babies.18 Kernicterus in adults is a rare condition. To date, there are only two published cases.19,20 In one case, the disorder was associated with liver failure.19 The other case was an adult with CNS2, who developed kernicterus after laparoscopic surgery.20 This report describes two new cases of adult kernicterus associated with UGT1A1 mutations (CNS2).

CNS2 is usually caused by missense mutations in the UGT1A1 gene, which reduces enzyme activity but does not eliminate it.21,22 Most patients with CNS2 have homozygous missense mutations or compound heterozygous mutations.23 This explains the milder phenotype and inducibility of the residual enzyme activity by phenobarbital administration. Variants c.211G>A (p.G71R) and c.1456T>G (p.Y486D) are the most frequently reported mutation sites in Asian CNS2 patients.2426 In our patients, UGT1A1 sequencing analysis was performed. Patient 1 is a compound heterozygote with mutations c.-3279T>G, G71R, and S191F. His father and sister share the same UGT1A1 genotype as him, and were diagnosed with GS and CNS2, respectively. But none of them suffered from kernicterus. The above evidence suggests that the same genotype may result in different phenotypes and clinical manifestations. A possible explanation is that a multifactorial etiology including hormonal, environmental, and genetic factors contributes to the development of inherited diseases. Besides, liver histology suggested massive and submassive hepatocytes necrosis and cholestasis, consistent with ACLF and CNS2, respectively.27,28 Histopathology also showed steatosis, but the related mechanism is not clear. Before the onset of ACLF, Patient 1 drank about 20 g ethanol (500 mL beer) and then took traditional Chinese medicine for 1 week. Considering the relatively small intake of ethanol and the complex composition of Chinese medicine (although the composition is unknown), we speculated that Chinese medicine was the main cause of his acute liver injury, and eventually lead to his ACLF on the basis of Crigler-Najjar syndrome.

Patient 2 is heterozygous for the mutations G71R, R209W and M391K. The mutations G71R, S191F, and R209W are located in exon 1 of the UGT1A1 gene, and have been shown to be associated with CNS2 (moderate hyperbilirubinemia).29 The mutation c.-3279T>G is located in the phenobarbital response enhancer module, which is related to GS (mild hyperbilirubinemia).30 The M391K mutation has not been reported yet. All prediction software indicated that the mutation is pathogenic. PhastCons and PhyloP showed a high degree of amino acid conservation, suggesting that the mutation has a great impact on amino acids and the protein. According to the variant classification criteria of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology,31 the novel M391K mutation is pathogenic to CNS2 in this patient. The effect on the UGT1A1 enzyme’s activity needs to be further verified through cell experimentation. In summary, the mutation site, number, and genotype of UGT1A1 are related to bilirubin level.

The pathogenesis of kernicterus has not been fully elucidated but the main reason is excessive bilirubin production (i.e. hemolysis) and/or insufficient liver glucuronidation, leading to higher levels of free unbound bilirubin. The potential mechanism of UCB neurotoxicity is shown in Fig. 5.18 In our two patients, CNS2 reduced bilirubin glucuronidation. Infection, fever and liver injury cause a decrease in serum albumin levels. Therefore, free unbound bilirubin increased. In infants, a bilirubin-albumin molar ratio (referred to as BAMR) value >0.8 is considered dangerous because bilirubin/albumin binding is unpredictable at these levels.17 However, for adults, the BAMR value predicting kernicterus is still unclear. In our two patients, bilirubin concentrations increased to 616 µmol/L and 547 µmol/L, respectively, with BAMR value >0.8 in both. Then, kernicterus occurred. Therefore, for patients with CNS2, it is important to avoid particularly high bilirubin levels and maintain normal serum albumin levels.

Cell types and metabolic processes affected by bilirubin in the central nervous system.
Fig. 5  Cell types and metabolic processes affected by bilirubin in the central nervous system.

The main effects of bilirubin on neurons are decreased oxygen consumption and increased release of calcium and caspase 3, resulting in apoptosis. There is also decreased dendritic and axonal arborization. A similar pattern is observed in oligodendrocytes with increased apoptosis, impairment of the redox state (oxidative stress), and reduced synthesis of myelin. Microglia react to toxic injury associated with bilirubin by increased release of proinflammatory cytokines and metalloproteinase activity as cells manifest a phagocytic phenotype. A similar proinflammatory pattern is observed in astrocytes, with enhanced release of glutamate and apoptosis. At the same time, cells may reduce the intracellular concentration of bilirubin either by extruding the pigment through the ATP-binding cassette transporters or by increasing the formation of the less toxic products through bilirubin oxidation products (BOXes) and/or cytochrome P-450 enzymes (1a1 and 1a2, in particular). These responses are protective, whereas all others result in cell damage; this suggests that once the intracellular concentration of bilirubin exceeds a toxic threshold (still to be defined), the polymorphic metabolic cascade leading to neurotoxicity ensues. (From Watchko JF, Tiribelli C. Bilirubin-induced neurologic damage-mechanism and management approaches. N Engl J Med 2013; 369: 2025). Abbreviations: cPARP, cleaved poly (adenosine diphosphate-ribose) polymerase; TER, transcellular resistance.

Infection, liver damage, and hemolytic disease should also be avoided. It should be noted that CNS2 patients respond to phenobarbital. To prevent severe hyperbilirubinemia and kernicterus, phenobarbital therapy should be adhered to. If the patient develops kernicterus, treatments that eliminate the cause, or those such as albumin supplementation and artificial liver support treatment, are effective. Due to severe necrosis and insufficient regeneration of hepatocytes in patient 1, the bilirubin level still slightly fluctuated in the case of artificial liver support treatment. At the same time, although the patient recovered consciousness after albumin supplementation and artificial liver support treatment, increased bilirubin due to CNS2 may lead to recurrence of kernicterus. At present, liver transplantation is the only treatment option that completely replaces UGT1A1 function and normalizes serum bilirubin levels.

In conclusion, although very rare, adults with CNS2 are at risk of kernicterus. Phenobarbital administration helps maintain bilirubin levels and prevent kernicterus.

Supporting information

Supplementary Fig. 1

Imaging findings for patient 1.

Computed tomography (CT) (A) and magnetic resonance imaging (B) of the abdomen showed hepatosplenomegaly. No reduction in signal intensity of the liver parenchyma was found in the out-of-phase image (C). The T2WI image showed a diffuse and mild increase in the signal intensity of the liver parenchyma (D). The brain CT scan was normal (E).

(TIF)

Supplementary Fig. 2

Sanger sequencing of patient 1.

Three heterozygous mutations were found in the UGT1A1 gene of patient 1: c.-3279T>G, c.211G>A (p.G71R), and c.572C>T (p.S191F). II:1, patient 1; I:1, the patient’s father; I:2, the patient’s mother; II:2, the patient’s sister; III:1, the patient’s son; III:2, the patient’s nephew (the son of the patient’s sister).

(TIF)

Supplementary Fig. 3

Sanger sequencing of patient 2.

Three heterozygous mutations were found in the UGT1A1 gene of patient 2: c.211G>A (p.G71R), c. 625C>T (p.R209W), and c.1172T>A (p.M391K).

(TIF)

Supplementary Table 1

Bioinformatics analysis of the novel UGT1A1 mutation c. 1172T>A (p. M391K)

(DOCX)

Abbreviations

ACLF: 

acute-on-chronic liver failure

ALT: 

alanine aminotransferase

AST: 

aspartate aminotransferase

BAMR: 

bilirubin-albumin molar ratio

CNS2: 

Crigler-Najjar syndrome type II

CT: 

computed tomography

DPMAS: 

double plasma molecular adsorption system combined with plasma exchange

GS: 

Gilbert syndrome

Ig: 

immunoglobulin

TB: 

total bilirubin

UCB: 

unconjugated bilirubin

UGT1A1: 

uridine diphosphate glucuronosyl transferase 1A1

Declarations

Funding

This study was supported by Beijing Municipal Science and Technology Project (No. Z171100002217070), National Key R&D Program of China (No. 2017YFA0103000), National Science and Technology Key Project on “Major Infectious Diseases such as HIV/AIDS, Viral Hepatitis Prevention and Treatment” (Nos. 2012ZX10002004-006, 2017ZX10203201-005, 2017ZX10201201, 2017ZX10202203-006-001 and 2017ZX10302201-004-002), “Beijing Municipal Administration of Hospitals” Ascent Plan (No. DFL20151601), Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (Nos. ZYLX201806 and ZYLX202125), Digestive Medical Coordinated Development Center of Beijing Municipal Administration of Hospitals (No. XXZ0503), You An Fund for Liver Diseases and AIDS (No. YNKTTS201801189), Beijing Municipal Natural Science Foundation (No. 7202068).

Conflict of interest

The authors have no conflict of interests related to this publication.

Authors’ contributions

Conception and design (JB, LL, SZ, ZD), patient recruitment (JB, LL), data collection (HL, SL, LB, WS), data analysis (JB, LL, HL, WS), writing the draft (JB, LL), revising and polishing the manuscript (JB, LL, YC, SZ, ZD). All authors read and approved the final manuscript.

References

  1. Olusanya BO, Kaplan M, Hansen TWR. Neonatal hyperbilirubinaemia: a global perspective. Lancet Child Adolesc Health 2018;2:610-620 View Article
  2. Olusanya BO, Ogunlesi TA, Slusher TM. Why is kernicterus still a major cause of death and disability in low-income and middle-income countries?. Arch Dis Child 2014;99:1117-1121 View Article
  3. Muchowski KE. Evaluation and treatment of neonatal hyperbilirubinemia. Am Fam Physician 2014;89:873-878
  4. Okolie F, South-Paul JE, Watchko JF. Combating the hidden health disparity of kernicterus in black infants: A review. JAMA Pediatr 2020;174(12):1199-1205 View Article
  5. Lin JP, Cupples LA, Wilson PW, Heard-Costa N, O’Donnell CJ. Evidence for a gene influencing serum bilirubin on chromosome 2q telomere: a genomewide scan in the Framingham study. Am J Hum Genet 2003;72:1029-1034 View Article
  6. Strassburg CP. Hyperbilirubinemia syndromes (Gilbert-Meulengracht, Crigler-Najjar, Dubin-Johnson, and Rotor syndrome). Best Pract Res Clin Gastroenterol 2010;24:555-571 View Article
  7. Ebrahimi A, Rahim F. Crigler-Najjar syndrome: Current perspectives and the application of clinical genetics. Endocr Metab Immune Disord Drug Targets 2018;18:201-211 View Article
  8. Crigler JF, Najjar VA. Congenital familial nonhemolytic jaundice with kernicterus. Pediatrics 1952;10:169-180
  9. Crigler JF, Najjar VA. Congenital familial nonhemolytic jaundice with kernicterus; a new clinical entity. AMA Am J Dis Child 1952;83:259-260
  10. van Dijk R, Beuers U, Bosma PJ. Gene replacement therapy for genetic hepatocellular jaundice. Clin Rev Allergy Immunol 2015;48:243-253 View Article
  11. Fagiuoli S, Daina E, D’Antiga L, Colledan M, Remuzzi G. Monogenic diseases that can be cured by liver transplantation. J Hepatol 2013;59:595-612 View Article
  12. Wagner KH, Shiels RG, Lang CA, Seyed Khoei N, Bulmer AC. Diagnostic criteria and contributors to Gilbert’s syndrome. Crit Rev Clin Lab Sci 2018;55:129-139 View Article
  13. Erlinger S, Arias IM, Dhumeaux D. Inherited disorders of bilirubin transport and conjugation: new insights into molecular mechanisms and consequences. Gastroenterology 2014;146:1625-1638 View Article
  14. Strauss KA, Robinson DL, Vreman HJ, Puffenberger EG, Hart G, Morton DH. Management of hyperbilirubinemia and prevention of kernicterus in 20 patients with Crigler-Najjar disease. Eur J Pediatr 2006;165:306-319 View Article
  15. Poddar B, Bharti B, Goraya J, Parmar VR. Kernicterus in a child with Crigler-Najjar Syndrome Type II. Trop Gastroenterol 2002;23:33-34
  16. Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert’s syndrome. N Engl J Med 1995;333:1171-1175 View Article
  17. Wallenstein MB, Bhutani VK. Jaundice and kernicterus in the moderately preterm infant. Clin Perinatol 2013;40:679-688 View Article
  18. Watchko JF, Tiribelli C. Bilirubin-induced neurologic damage—mechanisms and management approaches. N Engl J Med 2013;369:2021-2030 View Article
  19. Waser M, Kleihues P, Frick P. Kernicterus in an adult. Ann Neurol 1986;19:595-598 View Article
  20. Chalasani N, Chowdhury NR, Chowdhury JR, Boyer TD. Kernicterus in an adult who is heterozygous for Crigler-Najjar syndrome and homozygous for Gilbert-type genetic defect. Gastroenterology 1997;112:2099-2103 View Article
  21. Clarke DJ, Moghrabi N, Monaghan G, Cassidy A, Boxer M, Hume R, et al. Genetic defects of the UDP-glucuronosyltransferase-1 (UGT1) gene that cause familial non-haemolytic unconjugated hyperbilirubinaemias. Clin Chim Acta 1997;266:63-74 View Article
  22. Kadakol A, Ghosh SS, Sappal BS, Sharma G, Chowdhury JR, Chowdhury NR. Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: correlation of genotype to phenotype. Hum Mutat 2000;16:297-306
  23. Servedio V, d’Apolito M, Maiorano N, Minuti B, Torricelli F, Ronchi F, et al. Spectrum of UGT1A1 mutations in Crigler-Najjar (CN) syndrome patients: identification of twelve novel alleles and genotype-phenotype correlation. Hum Mutat 2005;25:325 View Article
  24. Zheng B, Hu G, Yu J, Liu Z. Crigler-Najjar syndrome type II in a Chinese boy resulting from three mutations in the bilirubin uridine 5′-diphosphate-glucuronosyltransferase (UGT1A1) gene and a family genetic analysis. BMC Pediatr 2014;14:267 View Article
  25. Yanagi T, Nakahara S, Maruo Y. Bilirubin uridine diphosphate-glucuronosyltransferase polymorphism as a risk factor for prolonged hyperbilirubinemia in Japanese preterm infants. J Pediatr 2017;190:159-162.e1 View Article
  26. Maruo Y, Nakahara S, Yanagi T, Nomura A, Mimura Y, Matsui K, et al. Genotype of UGT1A1 and phenotype correlation between Crigler-Najjar syndrome type II and Gilbert syndrome. J Gastroenterol Hepatol 2016;31:403-408 View Article
  27. Fata CR, Gillis LA, Pacheco MC. Liver fibrosis associated with crigler-najjar syndrome in a compound heterozygote: A case report. Pediatr Dev Pathol 2017;20:522-525 View Article
  28. Sarin SK, Choudhury A, Sharma MK, Maiwall R, Al Mahtab M, Rahman S, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol Int 2019;13:353-390 View Article
  29. Sneitz N, Bakker CT, de Knegt RJ, Halley DJ, Finel M, Bosma PJ. Crigler-Najjar syndrome in The Netherlands: identification of four novel UGT1A1 alleles, genotype-phenotype correlation, and functional analysis of 10 missense mutants. Hum Mutat 2010;31:52-59 View Article
  30. Bai J, Luo L, Liu S, Liang C, Bai L, Chen Y, et al. Combined effects of UGT1A1 and SLCO1B1 variants on Chinese adult mild unconjugated hyperbilirubinemia. Front Genet 2019;10:1073 View Article
  31. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17:405-424 View Article
  • Journal of Clinical and Translational Hepatology
  • pISSN 2225-0719
  • eISSN 2310-8819

UGT1A1-related Bilirubin Encephalopathy/Kernicterus in Adults

Jie Bai, Lu Li, Hui Liu, Shuang Liu, Li Bai, Wenyan Song, Yu Chen, Sujun Zheng, Zhongping Duan
  • Reset Zoom
  • Download TIFF